CN102666850A - 因子d和抗因子d抗体的共晶结构 - Google Patents

因子d和抗因子d抗体的共晶结构 Download PDF

Info

Publication number
CN102666850A
CN102666850A CN2010800568895A CN201080056889A CN102666850A CN 102666850 A CN102666850 A CN 102666850A CN 2010800568895 A CN2010800568895 A CN 2010800568895A CN 201080056889 A CN201080056889 A CN 201080056889A CN 102666850 A CN102666850 A CN 102666850A
Authority
CN
China
Prior art keywords
factor
antibody
polypeptide
crystal
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800568895A
Other languages
English (en)
Chinese (zh)
Inventor
门诺·凡卢克伦·康帕涅
克里斯蒂安·维斯曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN102666850A publication Critical patent/CN102666850A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
CN2010800568895A 2009-11-04 2010-11-04 因子d和抗因子d抗体的共晶结构 Pending CN102666850A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28046009P 2009-11-04 2009-11-04
US61/280,460 2009-11-04
US28171609P 2009-11-20 2009-11-20
US61/281,716 2009-11-20
PCT/US2010/055509 WO2011057014A1 (en) 2009-11-04 2010-11-04 Co-crystal structure of factor d and anti-factor d antibody

Publications (1)

Publication Number Publication Date
CN102666850A true CN102666850A (zh) 2012-09-12

Family

ID=43303899

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800568895A Pending CN102666850A (zh) 2009-11-04 2010-11-04 因子d和抗因子d抗体的共晶结构

Country Status (14)

Country Link
US (1) US20110165648A1 (https=)
EP (1) EP2496695A1 (https=)
JP (1) JP2013509866A (https=)
KR (1) KR20120120153A (https=)
CN (1) CN102666850A (https=)
AR (1) AR078886A1 (https=)
BR (1) BR112012011607A2 (https=)
CA (1) CA2782481A1 (https=)
IN (1) IN2012DN03338A (https=)
MX (1) MX2012005430A (https=)
RU (1) RU2012122700A (https=)
TW (1) TW201121993A (https=)
WO (1) WO2011057014A1 (https=)
ZA (1) ZA201202602B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103724433B (zh) * 2008-04-28 2015-11-18 健泰科生物技术公司 人源化抗因子d抗体及其用途

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
AU2014306867B2 (en) 2013-08-12 2017-10-26 Genentech, Inc. Compositions and method for treating complement-associated conditions
JP6463361B2 (ja) 2013-09-08 2019-01-30 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
EP3137503A1 (en) 2014-05-01 2017-03-08 Genentech, Inc. Anti-factor d antibody variants and uses thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
US20170137535A1 (en) * 2015-10-30 2017-05-18 Genentech, Inc. Anti-factor d antibody formulations
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
EP3405577B8 (en) * 2016-01-20 2023-02-15 396419 B.C. Ltd. Compositions and methods for inhibiting factor d
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
CA3059938A1 (en) * 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291160B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6291161B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DK0494955T3 (da) 1989-10-05 1998-10-26 Optein Inc Cellefri syntese og isolering af hidtil ukendte gener og polypeptider
US5244800A (en) * 1990-04-27 1993-09-14 The Uab Research Foundation Crystals of human complement factor d that are triclinic
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
CN106188303A (zh) * 2006-11-02 2016-12-07 健泰科生物技术公司 人源化的抗‑d因子抗体
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) * 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103724433B (zh) * 2008-04-28 2015-11-18 健泰科生物技术公司 人源化抗因子d抗体及其用途

Also Published As

Publication number Publication date
JP2013509866A (ja) 2013-03-21
US20110165648A1 (en) 2011-07-07
MX2012005430A (es) 2012-06-19
CA2782481A1 (en) 2011-05-12
AR078886A1 (es) 2011-12-07
RU2012122700A (ru) 2013-12-10
TW201121993A (en) 2011-07-01
WO2011057014A1 (en) 2011-05-12
KR20120120153A (ko) 2012-11-01
EP2496695A1 (en) 2012-09-12
ZA201202602B (en) 2013-06-26
IN2012DN03338A (https=) 2015-10-23
BR112012011607A2 (pt) 2020-06-02

Similar Documents

Publication Publication Date Title
CN102666850A (zh) 因子d和抗因子d抗体的共晶结构
CN101754980B (zh) 补体相关眼疾的预防和治疗
CN102066419B (zh) 人源化抗因子d抗体及其用途
JP6750010B2 (ja) 抗ＨｔｒＡ１抗体及びその使用方法
US20180037667A1 (en) Anti-factor b antibodies and their uses
AU2017254945A1 (en) Prevention and treatment of complement-associated eye conditions
HK1174360A (en) Co-crystal structure of factor d and anti-factor d antibody
AU2013213753A1 (en) Prevention and treatment of complement-associated eye conditions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1174360

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120912